XML 27 R16.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Share Capital | 6 Months Ended
--- | ---
Dec. 31, 2021
Share Capital |
Share Capital | 11. Share Capital a) Authorized capital Unlimited number of common voting shares without nominal or par value Unlimited number of preferred shares without par value issued in one or more series 161,032,217 common shares were issued and outstanding at December 31, 2021. On October 1, 2020, the Company issued 500,000 common shares with a fair value of $1,025,000 to Nevada Alaska Mining Co. Ltd. (Note 3). On December 18, 2020, the Company closed a prospectus financing of 15,697,500 common shares at a price of $2.20 for aggregate gross proceeds of $34,534,500. The Company incurred $2,666,812 of share issuance costs related to the financing. On April 23, 2021, the Company issued 400,000 common shares with a fair value of $1,600,000 to TETRA Technologies, Inc. (Note 3). On May 21, 2021, the Company issued 200,000 common shares with a fair value of $786,000 to National Chloride. (Note 3). On June 10, 2021, the Company issued 6,251,250 common shares to Lanxess Corporation upon the conversion of the convertible loan (Note 7). During the year ended June 30, 2021, the Company issued a total of 11,245,133 common shares for the exercise of share purchase warrants. The Company received proceeds of $10,190,569 upon exercise. As at June 30, 2021, the Company held $39,000 as a receivable from the Company’s transfer agent which was received by the Company on July 21, 2021. During the year ended June 30, 2021, the Company issued a total of 1,375,000 common shares for the exercise of stock options. The Company received proceeds of $1,241,500 upon exercise and transferred $981,261 from contributed surplus to share capital. On November 30, 2021, the Company closed a non-brokered private placement of 13,480,083 common shares at a price of $9.43 per share for gross proceeds of $127,070,000. In connection with the closing of the private placement, the Company paid a cash finders’ fee of $6,384,050, issued 336,877 finders’ warrants with a fair value of $2,211,663 and incurred $233,598 of additional share issuance costs. All shares and finders’ warrants are restricted for resale until March 31, 2021. The fair value of the finders warrants was calculated using the Black-Scholes option pricing model using an annualized volatility of 83%, a risk-free interest rate of 0.92%, a dividend rate of 0%, an expected life of 2 years and a share price on grant date of $13.23. During the six months ended December 31, 2021, the Company issued a total of 5,635,147 common shares for the exercise of share purchase warrants for gross proceeds of $6,306,982. During the six months ended December 31, 2021, the Company issued a total of 750,784 common shares for the exercise of stock options. The Company received proceeds of $745,500 and reclassified $952,780 from reserves to share capital upon exercise. b) Warrants Warrant transactions are summarized as follows:
Disclosure of detail information about warrants |  |  |  |  |  |  |  |
|  | Number of warrants |  | Weighted average exercise price
Balance at June 30, 2020 |  |  | 18,074,695 |  |  |  | 0.98 |
Expired |  |  | (141,317 | ) |  |  | 1.00 |
Exercised |  |  | (11,245,133 | ) |  |  | 0.93 |
Issued |  |  | 3,125,625 |  |  |  | 1.20 |
Balance at June 30, 2021 |  |  | 9,813,870 |  |  |  | 1.13 |
Issued |  |  | 336,877 |  |  |  | 11.09 |
Exercised |  |  | (5,635,147 | ) |  |  | 1.12 |
Balance at December 31, 2021 |  |  | 4,515,600 |  |  |  | 1.90 |
The weighted average contractual life of the warrants outstanding is 0.94 years. c) Options The Company has a stock option plan in place under which it is authorized to grant options to officers, directors, employees, consultants and management company employees enabling them to acquire up to 10% of the issued and outstanding common stock of the Company. Under the plan, the exercise price of each option shall not be less than the price permitted by any stock exchange. The options can be granted for a maximum term of 10 years. c) Options – continued On August 9, 2020, the Company extended the expiration date of 435,784 stock options issued to consultants from August 9, 2020 to August 9, 2021. The exercise price of the options remains $1.02 per option. On January 18, 2021, the Company granted 1,200,000 stock options to directors and officers of the Company at a price of $3.39 for a period of 5 years. All of the stock options vested at grant. On April 13, 2021, the Company granted 400,000 stock options to consultants of the Company at a price of $3.43 for a period of three (3) years with the stock options vesting one quarter at grant, one quarter three months from grant date, one quarter at six months from grant date and one quarter at nine months from grant date. On July 20, 2021, The Company granted 200,000 stock options to a director of the Company at a price of $6.08 for a period of 5 years. All of the stock options vested at grant. The following weighted average assumptions were used for the Black-Scholes valuation of stock options granted:
Disclosure of weighted average assumptions were used for the Black-Scholes valuation of stock options granted |  |  |  |  |  |  |  |
|  |  | 2021 |  |  |  | 2020 |
Annualized volatility |  |  | 81 | % |  |  | 114 | %
Risk-free interest rate |  |  | 0.73 | % |  |  | 0.56 | %
Dividend rate |  |  | 0 | % |  |  | 0 | %
Expected life of options (years) |  |  | 5 |  |  |  | 4 |
Forfeiture rate |  |  | 0 | % |  |  | 0 | %
Share price on grant date |  | $ | 6.08 |  |  | $ | 3.41 |
Stock option transactions are summarized as follows:
Disclosure of Stock option transactions |  |  |  |  |  |  |  |
|  |  | Number of options |  |  |  | Weighted average exercise price |
Balance at June 30, 2020 |  |  | 13,525,784 |  |  | $ | 0.99 |
Options exercised |  |  | (1,375,000 | ) |  |  | 0.90 |
Options granted |  |  | 1,600,000 |  |  |  | 3.40 |
Balance at June 30, 2021 |  |  | 13,750,784 |  |  |  | 1.29 |
Options exercised |  |  | (750,784 | ) |  |  | 0.99 |
Options granted |  |  | 200,000 |  |  |  | 6.08 |
Balance at December 31, 2021 |  |  | 13,200,000 |  |  |  | 1.37 |
The following table summarizes stock options outstanding and exercisable at December 31, 2021:
| Disclosure of stock options outstanding and exercisable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  | Options Outstanding |  |  |  | Options Exercisable |
|  |  |  |  |  |  |  |  | Weighted |  |  |  | Weighted |  |  |  |  |  |  |  | Weighted |
|  |  |  |  |  |  |  |  | Average |  |  |  | Average |  |  |  |  |  |  |  | Average |
| Exercise |  |  |  | Number |  |  |  | Remaining |  |  |  | Exercise |  |  |  |  |  |  |  | Exercise |
| Price |  |  |  | of |  |  |  | Contractual Life |  |  |  | Price |  |  |  | Number |  |  |  | Price |
| $ |  |  |  | Shares |  |  |  | (years) |  |  |  | $ |  |  |  | Exercisable |  |  |  | $ |
| 1.05 |  |  |  | 1,000,000 |  |  |  | 0.17 |  |  |  | 1.05 |  |  |  | 1,000,000 |  |  |  | 1.05 |
| 0.96 |  |  |  | 2,340,000 |  |  |  | 0.46 |  |  |  | 0.96 |  |  |  | 2,340,000 |  |  |  | 0.96 |
| 2.10 |  |  |  | 500,000 |  |  |  | 1.14 |  |  |  | 2.10 |  |  |  | 500,000 |  |  |  | 2.10 |
| 1.40 |  |  |  | 1,900,000 |  |  |  | 1.68 |  |  |  | 1.40 |  |  |  | 1,900,000 |  |  |  | 1.40 |
| 1.00 |  |  |  | 460,000 |  |  |  | 0.25 |  |  |  | 1.00 |  |  |  | 460,000 |  |  |  | 1.00 |
| 0.75 |  |  |  | 150,000 |  |  |  | 1.79 |  |  |  | 0.75 |  |  |  | 150,000 |  |  |  | 0.75 |
| 0.76 |  |  |  | 4,450,000 |  |  |  | 1.19 |  |  |  | 0.76 |  |  |  | 4,450,000 |  |  |  | 0.76 |
| 0.75 |  |  |  | 500,000 |  |  |  | 1.34 |  |  |  | 0.75 |  |  |  | 500,000 |  |  |  | 0.75 |
| 0.81 |  |  |  | 100,000 |  |  |  | 1.36 |  |  |  | 0.81 |  |  |  | 100,000 |  |  |  | 0.81 |
| 3.39 |  |  |  | 1,200,000 |  |  |  | 4.05 |  |  |  | 3.39 |  |  |  | 1,200,000 |  |  |  | 3.39 |
| 3.43 |  |  |  | 400,000 |  |  |  | 2.28 |  |  |  | 3.43 |  |  |  | 300,000 |  |  |  | 3.43 |
| 6.08 |  |  |  | 200,000 |  |  |  | 4.55 |  |  |  | 6.08 |  |  |  | 200,000 |  |  |  | 6.08 |
|  |  |  |  | 13,200,000 |  |  |  | 1.69 |  |  |  | 1.37 |  |  |  | 13,100,000 |  |  |  | 1.38 |

X
- Definition The disclosure of issued capital. [Refer: Issued capital] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfIssuedCapitalExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | sli_ShareCapitalAbstract
Namespace Prefix: | sli_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration